GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock Has Average Target Price of $4.23 According to Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been given an average rating of “Hold” by the thirteen analysts that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $4.23.

A number of brokerages have recently issued reports on GDRX. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $4.00 price target on shares of GoodRx in a research report on Friday, August 7th. Citigroup raised their price objective on GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Weiss Ratings upgraded GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, August 7th. UBS Group upped their target price on GoodRx from $2.50 to $3.75 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Finally, Barclays increased their price target on GoodRx from $3.00 to $4.00 and gave the company an “underweight” rating in a research note on Thursday, August 20th.

GoodRx Stock Performance

GDRX stock opened at $3.49 on Wednesday. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of 87.27, a PEG ratio of 1.76 and a beta of 1.69. The firm has a 50-day simple moving average of $3.43 and a two-hundred day simple moving average of $2.82. GoodRx has a one year low of $1.77 and a one year high of $3.89. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.38 and a current ratio of 1.38.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. The firm had revenue of $200.41 million for the quarter, compared to the consensus estimate of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.09 EPS. On average, equities analysts forecast that GoodRx will post 0.16 EPS for the current fiscal year.

Insider Buying and Selling

In other GoodRx news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $3.50, for a total transaction of $4,536,619.50. The transaction was disclosed in a filing with the SEC, which is available at this link. In the last ninety days, insiders have sold 2,760,995 shares of company stock valued at $9,673,207. 5.87% of the stock is owned by company insiders.

Institutional Investors Weigh In On GoodRx

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Headlands Technologies LLC acquired a new position in shares of GoodRx in the 2nd quarter valued at $30,000. Essential Partners LLC raised its stake in GoodRx by 375.4% in the 1st quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock worth $28,000 after acquiring an additional 11,295 shares during the last quarter. SG Americas Securities LLC acquired a new stake in GoodRx during the 1st quarter worth about $29,000. Krilogy Financial LLC acquired a new stake in GoodRx during the 1st quarter worth about $33,000. Finally, Amundi purchased a new stake in GoodRx during the 1st quarter valued at about $37,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc operates a digital healthcare platform that helps consumers find and access lower prices for prescription medications. Through its website and mobile applications, GoodRx allows users to compare prices at participating pharmacies, obtain prescription discount coupons and identify potential savings on commonly prescribed drugs. The company’s services are generally available at pharmacies across the United States.

GoodRx also offers GoodRx Gold, a membership program that provides additional discounts on eligible prescriptions, as well as healthcare-related content and tools designed to help consumers understand medications and treatment options.